Keros doses first patient in Phase 2 rinvatercept trial for Duchenne muscular dystrophy

Bitget2026/09/28 12:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Keros Therapeutics dosed the first patient in a Phase 2 trial of rinvatercept for Duchenne muscular dystrophy.
Initial results have not been presented; early data are expected in the first half of 2027.
The study is intended to assess whether rinvatercept can improve outcomes for both ambulatory and non-ambulatory DMD patients.
The milestone advances Keros’s neuromuscular pipeline, setting up a key clinical readout that could shape its development strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001664710-26-000056), on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Yardeni Research has lowered its year-end S&P 500 target to 7,900 points and reduced its valuation target to 18.6 times, mainly due to risk-off sentiment suppressing valuations rather than deteriorating earnings. Despite facing risk aversion and policy risks, Yardeni remains optimistic about corporate earnings and the medium-to-long-term economy, viewing pullbacks as buying opportunities.

华尔街见闻•2026/10/15 13:26